Eton Pharmaceuticals, Inc.

NasdaqGM:ETON Rapporto sulle azioni

Cap. di mercato: US$258.9m

Eton Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Eton Pharmaceuticals ha un patrimonio netto totale di $16.0M e un debito totale di $4.1M, che porta il suo rapporto debito/patrimonio netto a 25.8%. Le sue attività totali e le sue passività totali sono rispettivamente $35.8M e $19.9M.

Informazioni chiave

25.8%

Rapporto debito/patrimonio netto

US$4.13m

Debito

Indice di copertura degli interessin/a
ContantiUS$20.26m
Patrimonio nettoUS$15.98m
Totale passivitàUS$19.86m
Totale attivitàUS$35.84m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%

Nov 14
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%

Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?

Oct 07
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?

After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar

Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%

The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot

Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point

Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money

Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Dec 22
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous

Sep 13

Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story

Aug 14

Eton Pharma jumps 20% on FDA approval of seizure therapy

Jul 18

Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Apr 15
Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Oct 14
Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Another Look At Eton Pharmaceuticals

Sep 03

What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Aug 18
What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Eton Pharma wins FDA approval for Rezipres

Jun 15

FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment

May 28

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

May 15
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Apr 05
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Mar 01
Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Eton Pharma buys Canadian rights for Alkindi Sprinkle

Jan 14

Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

Jan 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $29.7M ) di ETON superano le sue passività a breve termine ( $19.7M ).

Passività a lungo termine: Le attività a breve termine di ETON ( $29.7M ) superano le sue passività a lungo termine ( $126.0K ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: ETON ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di ETON è aumentato da 0% a 25.8% negli ultimi 5 anni.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: ETON ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: Dati insufficienti per determinare se ETON ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.


Scoprire le aziende sane